title: Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute.
abstract: We evaluated the long-term outcome of very dose-intensive chemotherapy (TCC-NHL-91) for advanced intermediate-grade lymphoma, in which an eight-cycle regimen with 11 drugs was given with granulocyte colony-stimulating factor (G-CSF) support (total 18 weeks). Fifty-nine patients were treated during February 1, 1991 and March 31, 2001 (median age: 48 years). Forty-three patients (73%) were in a high-intermediate risk or high-risk group (HI/H) according to the age-adjusted International Prognostic Index (aa-IPI). Forty-six patients received 7 or 8 cycles of therapy. Ten of 15 patients over age 60 stopped before 7 cycles. Forty-three patients with an initial bulky mass or a residual mass received involved-field radiation. Overall, 56 patients (95%) achieved complete remission (CR). Grade 4 hematotoxicity was observed in all patients. With a median follow-up of 128 months, the 10-year overall survival (OS) and progression-free survival (PFS) rates were 76% and 61%, respectively. Neither aa-IPI risk factors nor the index itself was associated with response, OS, or PFS. One patient died of sepsis during the therapy and one died of secondary leukemia. This retrospective study suggests that the TCC-NHL-91 regimen achieves high CR, OS, and PFS in patients with advanced intermediate-grade lymphoma up to 60 years old and may be a valuable asset in the management of this disease. Further evaluation and prospective studies of the TCC-NHL-91 are warranted.
authors.affiliation: Division of Hematology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
authors.forename: Miyuki
authors.initials: M
authors.lastname: Akutsu
authors.forename: Saburo
authors.initials: S
authors.lastname: Tsunoda
authors.forename: Tohru
authors.initials: T
authors.lastname: Izumi
authors.forename: Masaru
authors.initials: M
authors.lastname: Tanaka
authors.forename: Susumu
authors.initials: S
authors.lastname: Katano
authors.forename: Koichi
authors.initials: K
authors.lastname: Inoue
authors.forename: Seiji
authors.initials: S
authors.lastname: Igarashi
authors.forename: Kaoru
authors.initials: K
authors.lastname: Hirabayashi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Furukawa
authors.forename: Ken
authors.initials: K
authors.lastname: Ohmine
authors.forename: Kazuya
authors.initials: K
authors.lastname: Sato
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Keiya
authors.initials: K
authors.lastname: Ozawa
authors.forename: Keita
authors.initials: K
authors.lastname: Kirito
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nagashima
authors.forename: Satoshi
authors.initials: S
authors.lastname: Teramukai
authors.forename: Masanori
authors.initials: M
authors.lastname: Fukushima
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Kano
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D053208:Kaplan-Meier Estimate; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone